ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1010

Elucidating the Activation Profile of Systemic Sclerosis Macrophages

Michael S. Ball1, Emilie P. Shipman1, Mohamed A. Eltanbouly1, Viktor Martyanov2, Kimberly A. Archambault3, Mary A. Carns4, Esperanza Arroyo4, Kathleen Aren4, Monique Hinchcliff5, Michael L. Whitfield2,3 and Patricia A. Pioli1, 1Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 4Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, 5Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Fibroblasts, Immune regulation, Macrophage, systemic sclerosis and transforming growth factor

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Genome-wide gene expression studies implicate macrophages (MØs) as mediators of fibrosis in systemic sclerosis (SSc) and our data indicate that MØs constitute the dominant inflammatory signature in SSc tissue. Because MØs are plastic and subject to modulation by local micro-environmental factors, in vivoMØ polarization spans a broad spectrum of activation states. Therefore, SSc MØ activation is likely shaped by the interplay of many factors, resulting in the development of an immuno-phenotype that supports disease development and progression. In this study, we define the activation profile of human SSc MØs as pro-fibrotic, and provide direct evidence that SSc MØs elicit activation of NFkappaB signaling pathways and proliferation in fibroblasts.

Methods: Plasma and PBMCs were obtained from whole blood of 14 SSc patients (disease duration <5 years) and from 5 healthy age and gender-matched control subjects following informed written consent. CD14+monocytes were isolated from PBMCs using magnetic bead selection, and were cultured with either autologous or allogeneic plasma for 7 days to differentiate the cells into MØs. Immune activation studies were performed using 10 ng/ml LPS. For reciprocal activation studies, SSc MØs were co-cultured with fibroblasts using Transwells. RNA expression in MØs and fibroblasts was analyzed using genome-wide analysis and RT-PCR, and protein expression and secretion were monitored using flow cytometry and by ELISA.

Results: Genome-wide expression profiling of human SSc MØs shows up-regulation of signaling pathways involved in antigen presentation and extracellular matrix organization. SSc MØs show an alternatively activated phenotype based on expression of cell surface markers, and express higher levels of TGF-beta and IL-6 under both basal and LPS-stimulated conditions. Differentiation of healthy MØs with SSc plasma results in enhanced TGF-beta and IL-6/JAK/STAT3 signaling pathway activation, and SSc-differentiated MØs co-cultured with dermal fibroblasts show enrichment of inflammatory and proliferation expression signatures. Dermal fibroblasts co-cultured with SSc-differentiated MØs show an activated phenotype.

Conclusion: The activation profile of SSc-differentiated MØs is pro-fibrotic. We demonstrate that SSc MØs are activated under basal conditions, and that these cells release mediators associated with both alternative and inflammatory MØ activation. For the first time, we show that co-culture of SSc MØs with fibroblasts induces fibroblast activation and proliferation. Intriguingly, these data suggest that activation of SSc MØs arises from soluble factors in local microenvironments. Collectively, these studies implicate MØs as likely drivers of fibrosis in SSc and suggest therapeutic targeting of these cells may be beneficial in ameliorating disease in SSc patients.


Disclosure: M. S. Ball, None; E. P. Shipman, None; M. A. Eltanbouly, None; V. Martyanov, None; K. A. Archambault, None; M. A. Carns, None; E. Arroyo, None; K. Aren, None; M. Hinchcliff, None; M. L. Whitfield, Gene expression biomarkers in SSc, 9,Celdara Medical LLC, 4; P. A. Pioli, Celdara Medical, LLC., 4.

To cite this abstract in AMA style:

Ball MS, Shipman EP, Eltanbouly MA, Martyanov V, Archambault KA, Carns MA, Arroyo E, Aren K, Hinchcliff M, Whitfield ML, Pioli PA. Elucidating the Activation Profile of Systemic Sclerosis Macrophages [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/elucidating-the-activation-profile-of-systemic-sclerosis-macrophages/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elucidating-the-activation-profile-of-systemic-sclerosis-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology